BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
327.75
-0.28 (-0.09%)
At close: 4:00PM EST

327.75 0.00 (0.00%)
After hours: 5:17PM EST

Stock chart is not supported by your current browser
Previous Close328.03
Open325.20
Bid326.00 x 100
Ask335.00 x 100
Day's Range323.84 - 327.90
52 Week Range244.28 - 348.84
Volume747,632
Avg. Volume1,259,268
Market Cap69.312B
Beta0.53
PE Ratio (TTM)20.13
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biogen Sees RS Rating Rise To 72
    Investor's Business Daily19 hours ago

    Biogen Sees RS Rating Rise To 72

    Biogen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Capital Cube6 days ago

    Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 88. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)

  • American City Business Journals7 days ago

    Biogen vet launches cancer drug startup with $50M from GV, others

    Michael Gilman, a former Biogen executive known for launching successful biotech startups, has pulled back the curtain on his latest project: a cancer drug developer backed by $49.5 million in financing from GV, Atlas Venture and others. Cambridge-based Obsidian Therapeutics came out of stealth mode on Wednesday, saying that it hopes to create an improved class of cell and gene therapies — so-called “living” drugs that reprogram a person’s immune cells to attack tumors. Obsidian was founded in 2015 by Atlas, which exclusively funded the company’s operations through mid-2017.

  • The Wall Street Journal7 days ago

    Biogen Seeks to Drive Neuroscience Innovation With CIO Hire

    Mark Hernon, a former regional IT chief at Takeda Pharmaceuticals, will oversee innovative IT tools that help develop treatments for Alzheimer’s, dementia and other neurological diseases, the biotech firm ...

  • GuruFocus.com7 days ago

    Primecap Management Buys Alkermes Biopharma

    Market-beating, media-shy firm picks biopharma with several drugs in final stages of approval

  • Capital Cube7 days ago

    ETFs with exposure to Biogen, Inc. : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : December 5, 2017
    Capital Cube8 days ago

    Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : December 5, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biogen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Barrons.com8 days ago

    [$$] Icahn Protege's Big Biotech Buys: Biogen, Medicines

    Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
    Zacks12 days ago

    The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt

    The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
    Zacks13 days ago

    Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

    The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

  • Top Research Reports for Amazon, AbbVie & Biogen
    Zacks13 days ago

    Top Research Reports for Amazon, AbbVie & Biogen

    Top Research Reports for Amazon, AbbVie & Biogen

  • Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal
    Zacks14 days ago

    Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

    While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

  • Barrons.com14 days ago

    Biogen's Next Big Drug Is…

    Shares of Biogen (BIIB) and Alkermes (ALKS) are both higher on Tuesday, after they announced a licensing agreement to develop and commercialize ALKS 8700, a multiple sclerosis treatment.  The drug, which ...

  • Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?
    Investor's Business Daily15 days ago

    Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?

    Biogen will pay Alkermes up to $228 million to gain another multiple sclerosis asset as key drug Tecfidera faces a patent cliff in the mid-2020s.

  • Biogen Inc. Buys Its Way Out of Competition
    Motley Fool15 days ago

    Biogen Inc. Buys Its Way Out of Competition

    The big biotech gains rights to a potential Tecfidera competitor from Alkermes.

  • Barrons.com15 days ago

    Biogen: If You Can't Beat 'em…

    In its quest to keep one of its cash cows pumping, biotech giant Biogen (BIIB) has applied a simple lesson: If you can't beat 'em, partner with them. Biogen, of course, makes Tecfidera, a blockbuster treatment that is expected to go off patent sometime in the early 2020's. Leerink's Geoffrey Porges and Bradley Canino explain how the Alkermes deal might help: This morning Biogen issued a press release stating that they had entered into a global licensing agreement with Alkermes (MP) to develop ALKS 8700, a monomethyl fumarate (MMF) pro-drug that is currently in phase III development for relapsing-remitting multiple sclerosis (RRMS). This announcement comes as a surprise, since ALKS 8700 was presumed to be one of several rivals, and risks, to the outlook for Biogen’s Tecfidera.

  • TODAY'S CHARTS: Retailers pop on Cyber Monday; Time surges on Meredith deal
    Yahoo Finance15 days ago

    TODAY'S CHARTS: Retailers pop on Cyber Monday; Time surges on Meredith deal

    Meanwhile, retailers like Best Buy (BBY), Gap (GPS) and JCPenney (JCP) are trading higher on some positive early Black Friday results. JCPenney’s website saw the most visits of any day so far this year. Shares of Time Inc. (TIME) are surging after Meredith (MDP) said it struck a deal to buy Time for $1.85 billion in cash, with a little help from the Kochs.

  • Investopedia15 days ago

    Biotechs Celgene, Biogen May Rally Through Yearend

    Year-end stock rallies by Biogen, Celgene and Amgen could buoy the biotech sector as 2018 approaches.

  • Reuters15 days ago

    Biogen boosts multiple sclerosis holding with Alkermes license

    Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera. Biogen's deal to buy the rights to develop and market Alkermes' MS drug comes after the drugmaker in January licensed Danish company Forward Pharma A/S's drug patents covering the same condition for $1.25 billion. Sales of Tecfidera, Biogen's bestselling MS drug, has slowed amid stiff competition from Roche AG's Ocrevus and Sanofi SA's Aubagio.

  • TheStreet.com15 days ago

    Alkermes Jumps on License Deal With Biogen -- Biotech Movers

    Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

  • MarketWatch16 days ago

    UPDATE: Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership

    Alkermes PLC shares rose 5.8% in premarket trade Monday on news of the company's partnership with Biogen Inc. on the multiple sclerosis drug ALKS 8700. Biogen shares were not active in premarket trade. ...

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $335 million.